Page 137 - 《中国药房》2022年11期

Toxicol，2013，9（8）：1037-1051. 2021，39（18）：2037-2048.
[ 5 ] MARTY M，FUMOLEAU P，ADENIS A，et al. Oral [16] KITZEN J J，PUOZZO C，DE JONGE M J，et al. Mild to
vinorelbine pharmacokinetics and absolute bioavailability moderate liver dysfunction does not require dose reduc-
study in patients with solid tumors[J]. Ann Oncol，2001， tion of oral or intravenous vinorelbine：results of a phar-
12（11）：1643-1649. macokinetic study[J]. Eur J Cancer，2010，46（2）：266-
[ 6 ] GUETZ S，TUFMAN A，VON PAWEL J，et al. Metrono- 269.
mic treatment of advanced non-small-cell lung cancer [17] GONG J，CHO M，GUPTA R，et al. A pilot study of
with daily oral vinorelbine：a phase Ⅰ trial[J]. Onco Tar- vinorelbine safety and pharmacokinetics in patients with
gets Ther，2017，10：1081-1089. varying degrees of liver dysfunction[J]. Oncologist，2019，
[ 7 ] CAPPELLANO A M，PETRILLI A S，DA SILVA N S， 24（8）：1137-1145.
et al. Single agent vinorelbine in pediatric patients with [18] CHEN C P，BUJANOVER S，KAREHT S，et al. Differen-
progressive optic pathway glioma[J]. J Neurooncol，2015， tial pharmacokinetics of diclofenac potassium for oral
121（2）：405-412. solution vs immediate-release tablets from a randomized
[ 8 ] KUTTESCH J F Jr，KRAILO M D，MADDEN T，et al. trial：effect of fed and fasting conditions[J]. Headache，
Phase Ⅱ evaluation of intravenous vinorelbine（Navel- 2015，55（2）：265-275.
bine）in recurrent or refractory pediatric malignancies：a [19] DELORD J P，PUOZZO C，LEFRESNE F，et al. Combi-
Children’s Oncology Group study[J]. Pediatr Blood Can- nation chemotherapy of vinorelbine and cisplatin：a phase
cer，2009，53（4）：590-593. Ⅰ pharmacokinetic study in patients with metastatic solid
[ 9 ] MINARD-COLIN V，ICHANTE J L，NGUYEN L，et al. tumors[J]. Anticancer Res，2009，29（2）：553-560.
Phase Ⅱ study of vinorelbine and continuous low doses [20] TOPLETZ A R，DENNISON J B，BARBUCH R J，et al.
cyclophosphamide in children and young adults with a The relative contributions of CYP3A4 and CYP3A5 to the
relapsed or refractory malignant solid tumour：good tole- metabolism of vinorelbine[J]. Drug Metab Dispos，2013，
rance profile and efficacy in rhabdomyosarcoma：a report 41（9）：1651-1661.
from the Société Française des Cancers et leucémies de [21] BONNETERRE J，CAMPONE M，KORALEWSKI P，
l’Enfant et de l’adolescent（SFCE）[J]. Eur J Cancer， et al. Vinorelbine/docetaxel combination treatment of me-
2012，48（15）：2409-2416. tastatic breast cancer：a phase Ⅰ study[J]. Cancer Che-
[10] JOHANSEN M，KUTTESCH J，BLEYER W A，et al. mother Pharmacol，2007，60（3）：365-373.
Phase Ⅰ evaluation of oral and intravenous vinorelbine in [22] NOLÈ F，CATANIA C，SANNA G，et al. Dose-finding
pediatric cancer patients：a report from the Children’s On- and pharmacokinetic study of an all-oral combination regi-
cology Group[J]. Clin Cancer Res，2006，12（2）：516-522. men of oral vinorelbine and capecitabine for patients with
[11] MARTIN L，BIRDSELL L，MACDONALD N，et al. Can- metastatic breast cancer[J]. Ann Oncol，2006，17（2）：322-
cer cachexia in the age of obesity：skeletal muscle deple- 329.
tion is a powerful prognostic factor，independent of body [23] LIU H R，YU Y Q，GUO N，et al. Application of physio-
mass index[J]. J Clin Oncol，2013，31（12）：1539-1547. logically based pharmacokinetic modeling to evaluate the
[12] VAN DOORN L，CROMBAG M R B S，RIER H N，et al. drug-drug and drug-disease interactions of apatinib[J].
The influence of body composition on the systemic expo- Front Pharmacol，2021，12：780937.
sure of paclitaxel in esophageal cancer patients[J]. Phar- [24] REZAI K，URIEN S，ISAMBERT N，et al. Pharmacokine-
maceuticals（Basel），2021，14（1）：47. tic evaluation of the vinorelbine-lapatinib combination in
[13] STEINMEYER Z，GÉRARD S，FILLERON T，et al. Low the treatment of breast cancer patients[J]. Cancer Che-
lean mass and chemotherapy toxicity risk in the elderly： mother Pharmacol，2011，68（6）：1529-1536.
the Fraction study protocol[J]. BMC Cancer，2019，19（1）： [25] FERRARIO C，STREPPONI I，ESFAHANI K，et al. Phase
1153. Ⅰ/Ⅱ trial of sorafenib in combination with vinorelbine as
[14] SJØBLOM B，BENTH J Š，GRØNBERG B H，et al. Drug first-line chemotherapy for metastatic breast cancer[J].
dose per kilogram lean body mass predicts hematologic PLoS One，2016，11（12）：e0167906.
toxicity from carboplatin-doublet chemotherapy in ad- [26] AWADA A，DIRIX L，MANSO SANCHEZ L，et al. Safe-
vanced non-small-cell lung cancer[J]. Clin Lung Cancer， ty and efficacy of neratinib（HKI-272）plus vinorelbine in
2017，18（2）：e129-e136. the treatment of patients with ErbB2-positive metastatic
[15] GRIGGS J J，BOHLKE K，BALABAN E P，et al. Appro- breast cancer pretreated with anti-HER2 therapy[J]. Ann
priate systemic therapy dosing for obese adult patients Oncol，2013，24（1）：109-116.
with cancer：ASCO guideline update[J]. J Clin Oncol， [27] BAHLEDA R，VARGA A，BERGÉ Y，et al. Phase Ⅰ

中国药房 2022年第33卷第11期 China Pharmacy 2022 Vol. 33 No. 11 ·1407 ·